CO2024014799A2 - Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos - Google Patents
Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismosInfo
- Publication number
- CO2024014799A2 CO2024014799A2 CONC2024/0014799A CO2024014799A CO2024014799A2 CO 2024014799 A2 CO2024014799 A2 CO 2024014799A2 CO 2024014799 A CO2024014799 A CO 2024014799A CO 2024014799 A2 CO2024014799 A2 CO 2024014799A2
- Authority
- CO
- Colombia
- Prior art keywords
- bispecific antibodies
- binding domain
- methods
- same
- nrp1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263325312P | 2022-03-30 | 2022-03-30 | |
| US202263325317P | 2022-03-30 | 2022-03-30 | |
| PCT/US2023/016963 WO2023192514A1 (en) | 2022-03-30 | 2023-03-30 | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024014799A2 true CO2024014799A2 (es) | 2024-11-18 |
Family
ID=86184900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0014799A CO2024014799A2 (es) | 2022-03-30 | 2024-10-29 | Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240101682A1 (https=) |
| EP (1) | EP4499696A1 (https=) |
| JP (1) | JP2025511135A (https=) |
| KR (1) | KR20240163751A (https=) |
| CN (1) | CN119403831A (https=) |
| AU (1) | AU2023245728A1 (https=) |
| CA (1) | CA3255754A1 (https=) |
| CL (1) | CL2024002899A1 (https=) |
| CO (1) | CO2024014799A2 (https=) |
| CR (1) | CR20240462A (https=) |
| IL (1) | IL315960A (https=) |
| MX (1) | MX2024011978A (https=) |
| WO (1) | WO2023192514A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318499A (en) * | 2022-07-30 | 2025-03-01 | Pinetree Therapeutics Inc | Compounds for targeted lysosomal degradation and methods of using them |
| AU2023378712A1 (en) * | 2022-11-07 | 2025-05-01 | Pinetree Therapeutics, Inc. | Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| WO2017171373A2 (ko) * | 2016-03-29 | 2017-10-05 | 아주대학교산학협력단 | Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물 |
| KR102048474B1 (ko) * | 2016-03-29 | 2019-11-26 | 아주대학교산학협력단 | Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물 |
| CA3060190A1 (en) * | 2017-04-24 | 2018-11-01 | Ichnos Sciences SA | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers |
| WO2020027224A1 (ja) * | 2018-07-31 | 2020-02-06 | 国立大学法人東京大学 | 新たな結合特異性を抗体に付与する超汎用法 |
| WO2020079280A1 (en) * | 2018-10-19 | 2020-04-23 | Ichnos Sciences SA | T cell redirecting bispecific antibodies for the treatment of squamous cell cancers |
-
2023
- 2023-03-30 CN CN202380044206.1A patent/CN119403831A/zh active Pending
- 2023-03-30 CR CR20240462A patent/CR20240462A/es unknown
- 2023-03-30 CA CA3255754A patent/CA3255754A1/en active Pending
- 2023-03-30 KR KR1020247036173A patent/KR20240163751A/ko active Pending
- 2023-03-30 IL IL315960A patent/IL315960A/en unknown
- 2023-03-30 US US18/128,928 patent/US20240101682A1/en active Pending
- 2023-03-30 EP EP23719560.7A patent/EP4499696A1/en active Pending
- 2023-03-30 WO PCT/US2023/016963 patent/WO2023192514A1/en not_active Ceased
- 2023-03-30 AU AU2023245728A patent/AU2023245728A1/en active Pending
- 2023-03-30 JP JP2024557935A patent/JP2025511135A/ja active Pending
-
2024
- 2024-09-27 MX MX2024011978A patent/MX2024011978A/es unknown
- 2024-09-27 CL CL2024002899A patent/CL2024002899A1/es unknown
- 2024-10-29 CO CONC2024/0014799A patent/CO2024014799A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240163751A (ko) | 2024-11-19 |
| CL2024002899A1 (es) | 2025-02-07 |
| US20240101682A1 (en) | 2024-03-28 |
| CA3255754A1 (en) | 2023-10-05 |
| JP2025511135A (ja) | 2025-04-15 |
| EP4499696A1 (en) | 2025-02-05 |
| AU2023245728A1 (en) | 2024-09-26 |
| WO2023192514A1 (en) | 2023-10-05 |
| IL315960A (en) | 2024-11-01 |
| CN119403831A (zh) | 2025-02-07 |
| CR20240462A (es) | 2024-12-11 |
| MX2024011978A (es) | 2025-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024014799A2 (es) | Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos | |
| CL2021001686A1 (es) | Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378) | |
| MX2021015880A (es) | Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos. | |
| CO2021007053A2 (es) | Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn | |
| MX2020011828A (es) | Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos. | |
| EA202090718A1 (ru) | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) | |
| BR112023002895A2 (pt) | Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas | |
| EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
| MX2024010593A (es) | Anticuerpos 3e10 humanizados, variantes y fragmento de unión al antígeno de los mismos | |
| CO2022008314A2 (es) | Anticuerpos anti–mertk y métodos de uso de los mismos | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| CO2022000404A2 (es) | Fragmentos de unión a antígeno egfr y composiciones que los comprenden | |
| PE20241754A1 (es) | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden | |
| CL2022000230A1 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| BR112022009611A2 (pt) | Anticorpos anti-ror-2 e métodos de uso | |
| BR112021020532A2 (pt) | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 | |
| CO2022015049A2 (es) | Péptidos de dominios knob autónomos | |
| MX2024012474A (es) | Anticuerpos anti cumulo de diferenciacion 28 (cd28) y metodos de uso de los mismos | |
| MX2025010708A (es) | Composiciones anti-cd28 | |
| AR119382A1 (es) | Anticuerpos de pre-direccionamiento y métodos de uso | |
| PE20220566A1 (es) | ANTICUERPOS DE UNION A VISTA A pH ACIDO | |
| CO2023015859A2 (es) | Anticuerpos para tratar alfa-sinucleinopatías | |
| MX2025003940A (es) | Métodos para tratar cáncer con anticuerpos biespecíficos egfr x cd28 solos o en combinación con anticuerpos anti-pd-1 | |
| MX2022002363A (es) | Sistema receptor de antígeno quimérico y usos de este. | |
| PE20250796A1 (es) | Moleculas de union al antigeno anti-steap1 y sus usos |